Download PDF
Horm Metab Res 2003; 35(8): 492-497
DOI: 10.1055/s-2003-41807
Original Clinical
© Georg Thieme Verlag Stuttgart · New York

Ultrasonographic Thyroid Volume as a Reliable Prognostic Index of Radioiodine-131 Treatment Outcome in Graves’ Disease Hyperthyroidism

N.  Gómez-Arnaiz1 , E.  Andía2 , A.  Gumà2 , R.  Abós3 , J.  Soler1 , J.  M.  Gómez1
  • 1Department of Endocrinology
  • 2Department of Radiology
  • 3Department of Epidemiology, Ciutat Sanitària i Universitària de Bellvitge, Barcelona, Spain
Further Information

Publication History

Received 12 April 2002

Accepted after revision 14 February 2003

Publication Date:
02 September 2003 (online)

Also available at
    Permissions and Reprints

Abstract

Objective: We studied the relationship between thyroid volume, thyroid function and immunological markers of Graves’ disease (GD) to determine prognostic factors of treatment response to low-dose radioiodine-131 (131I). Material and methods: A prospective study of 40 patients with GD hyperthyroidism treated with 131I (141 ± 85MBq) and 10 GD patients who went spontaneously into remission (controls). Free T4, total T3 and basal TSH levels, TSH-receptor antibodies (TRAb) and anti-thyroid peroxidase antibodies (TPOAb) were studied. Thyroid volume was determined by ultrasonography. Logistic regression models were used to predict the probability of final thyroid status. Receiver-operating characteristics (ROC) curves and Hosmer Lemeshow tests were used to evaluate the final statistical models. Results: Of 40 patients treated with 131I, 16 became euthyroid, 12 hyperthyroid and 12 hypothyroid at 12 months. Median thyroid volume was reduced from 24.8 ml before to 8.5 ml at 12 months (p < 0.001). In 10 control patients, the median reduction was from 16.6 ml to 11.3 ml (p = 0.029). Thyroid volume reduction was lower in the hyperthyroid than in the euthyroid group, but higher in the hypothyroid group. Thyroid volume at baseline and at 3 months predicted hyperthyroidism outcome with a cut-off of 45 ml and 24.4 ml, respectively (odds ratio 1.074, p = 0.003, ROC curve 0.78 and odds ratio 1.182, p = 0.012, ROC curve 0.86 respectively). Thyroid volume at 6 months differentiated the hyperthyroid group with a cut-off of 17 ml. Thyroid volume at 3 and 6 months with a cut-off of 8.5 ml and 9.3 ml respectively, predicts permanent hypothyroidism outcome (odds ratio 0.768 and 0.685, p = 0.012 and p = 0.008, ROC curve 0.89 and 0.88, respectively). Changes in thyroid echogenicity and TRAb and TPOAb levels did not show any predictive value in the follow-up after 131I therapeutic outcome. Conclusion: The study shows that the ultrasonographic thyroid volume at 3 and 6 months after low-dose 131I treatment for GD hyperthyroidism could be a reliable prognostic factor of thyroid function outcome in the first year after treatment, and also reveals that the changes in the thyroid echogenicity and in the immunological markers of GD have no prognostic value.

Key words

Graves’ hyperthyroidism - Radioiodine-131 therapy - Thyroid volume - Thyroid echogenicity - Treatment outcome - TSH-receptor antibodies - Anti-thyroid peroxidase antibodies - Prognostic factors

References

  • 1 Kendall-Taylor P, Keir M J, Ross W M. Ablative radioiodine therapy for hyperthyroidism. Long-term follow-up study.  Br Med J. 1984;  289 361-363
    PubMedGoogle Scholar
  • 2 Sridama V, McCornlck M, Kaplan E L, Fauchet R, DeGroot L J. Long-term follow-up study of compensate low dose 131I therapy for Graves’ disease.  N Engl J Med. 1984;  16 426-432
    PubMedGoogle Scholar
  • 3 Goolden A WG, Stewart J SW. Long-term results from graded low-dose radioactive iodine therapy for thyrotoxicosis.  Clin Endocrinol (Oxf). 1986;  24 217-222
    PubMedGoogle Scholar
  • 4 Franklyn J A, Daykin J, Drolc Z, Farmer M, Sheppard M C. Long-term follow-up of treatment of thyrotoxicosis by three different methods.  Clin Endocrinol (Oxf). 1991;  34 71-76
    PubMedGoogle Scholar
  • 5 Nordike R A, Gilbert F I. Optimal iodine-131 dose for eliminating hyperthyroidism in Graves’ disease.  J Nucl Med. 1991;  32 487-496
    PubMedGoogle Scholar
  • 6 Leisner B. Ultrasound evaluation of thyroid diseases.  Horm Res. 1987;  26 33-41
    PubMedGoogle Scholar
  • 7 Berghout A, Wiersinga W M, Smits N J, Touber J L. The value of thyroid volume measured by ultrasonography in the diagnosis of goitre.  Clin Endocrinol (Oxf). 1998;  28 409-414
    PubMedGoogle Scholar
  • 8 Aizawa Y, Yoshida K, Kaise N, Kaise K, Fukazawa H, Kiso Y. Long-term effects of radioiodine on thyrotropin receptor antibodies in Graves’ disease.  Clin Endocrinol (Oxf). 1995;  42 517-522
    PubMedGoogle Scholar
  • 9 Rieu M, Raynaud A, Richard A, Laplanche S, Sambor B, Berrod J L. Evidence for the effect of antibodies to TSH receptors on the thyroid ultrasonographic volume in patients with Graves’ disease.  Clin Endocrinol (Oxf). 1994;  41 667-671
    PubMedGoogle Scholar
  • 10 Murakami Y, Takamatsu J, Sakane S, Kurna K, Ohsawa N. Changes in thyroid volume in response to radioactive iodine for Graves’ hyperthyroidism correlated with activity of thyroid-stimulating antibody and treatment outcome.  J Clin Endocrinol Metab. 1996;  81 3257-3260
    CrossrefPubMedGoogle Scholar
  • 11 Leslie W D, Peterdy A E, Dupont J O. Radioiodine treatment outcomes in thyroid glands previously irradiated for Graves’ hyperthyroidism.  J Nucl Med. 1988;  39 712-716
    PubMedGoogle Scholar
  • 12 Gómez N, Gómez J M, Orti A. et al . Transient hypothyroidism after iodine-131 therapy for Graves’ disease.  J Nucl Med. 1995;  36 1539-1542
    PubMedGoogle Scholar
  • 13 Brunn J, Block U, Ruf G, Bos L, Kunze W, Scriba P C. Volumetrie der Schilddrüsenlappen mittels realtime Sonographie.  Dtsch Med Wochenschr. 1981;  106 1338-1340
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Gómez J M, Maravall F J, Gómez N, Gumà A, Soler J. Determinants of thyroid volume as measured bu ultrasonography in healthy adults randomly selected.  Clin Endocrinol (Oxf). 2000;  53 629-634
    CrossrefPubMedGoogle Scholar
  • 15 Gómez-Arnaiz N, Gómez Sáez J M, Orti Llaveria A, Gavaldà Mestre L, Mairal Pairó L. Resultados del tratamiento de la enfermedad de Graves Basedow con 131I a dosis bajas calculadas.  Rev Clin Esp. 1998;  198 57-60
    PubMedGoogle Scholar
  • 16 Gómez J M, Gómez N, Amat M, Biondo S, Rafecas A, Jaurrieta E, Soler J. Hypothyroidism after iodine-131 or surgical therapy for Graves’ disease hyperthyroidism.  Ann Endocrinol. 2000;  61 184-191
    PubMedGoogle Scholar
  • 17 Virgili N, Gómez J M, Montaña E, Soler J, Castells M, Roca M. Short-term follow-up of patients with Graves’ disease treated with I131. The prevalence of transient hypothyroidism.  Rev Clin Esp. 1988;  183 300 - 303
    PubMedGoogle Scholar
  • 18 Müller-Gartner H W, Schneider C, Schroeder S. Autoimmune-resistance in Graves’ disease tissues: indication of a structural and functional heterogenicity.  Acta Endocrinol (Copenh). 1986;  113 233-241
    PubMedGoogle Scholar
  • 19 Chiovato L, Fiore E, Vittl P. et al . Outcome of thyroid function in Graves’ patients with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine- induced thyroid damage.  J Clin Endocrinol Metab. 1998;  83 40-46
    CrossrefPubMedGoogle Scholar
  • 20 Tsuruta M, Nagayama Y, Yokoyama N, Izumi M, Nagataki S. Long-term follow-up studies on iodine-131 treatment of hyperthyroid Graves’ disease based on the measurement of thyroid volume by ultrasonography.  Ann Nucl Med. 1993;  7 193-197
    PubMedGoogle Scholar
  • 21 Marcocci C, Gianchecchi O, Masini I. et al . A reappraisal of the role of methimazole and other factors on the efficacy and outcome of radioiodine therapy of Graves’ hyperthyroidism.  J Endocrinol lnves. 1990;  13 513-520
    PubMedGoogle Scholar
  • 22 Ralls P W, Mayekawa O S, Lee K P. et al . Color-flow doppler sonography in Graves’ disease: ”Thyroid inferno”.  Am J Roentg. 1988;  150 781-784
    CrossrefPubMedGoogle Scholar
  • 23 Vitti P, Raga T, Mancusi F. et al . Thyroid hypoechogenic pattern at ultrasanography as a tool for predicting recurrence of hyperthyroidism after medical treatment in patients with Graves’ disease.  Acta Endocrinol (Copenh). 1992;  126 128-131
    PubMedGoogle Scholar
  • 24 Zingrillo M, D’Aloiso L, Ghíggi M R. et al . Thyroid hypoechogenicity after methimazole withdrawal in Graves’ disease: a useful index for predicting recurrence?.  Clin Endocrinol (Oxf). 1996;  45 201-206
    CrossrefPubMedGoogle Scholar
  • 25 Macchia E, Concetti R, Borgoni F, Cetani F, Fenzi C F, Pinchera A. Assays of TSH-receptor antibodies in 576 patients with various thyroid disorders: their influence, significance and clinical usefulness.  Autoimmunity. 1989;  3 103-112
    PubMedGoogle Scholar
  • 26 Ludgate M E, Vassart G. The thyrotropin receptor.  Ball Clin Endocrinol Metab. 1995;  9 95-113
    PubMedGoogle Scholar
  • 27 Okamoto Y, Hamada N, Fujisawa T. et al . Why no simple relationship between thyroid peroxidase activity-inhibiting immunoglobulins and the thyroid function in autoimmune thyroid disease?.  Acta Endocrinol (Copenh). 1991;  124 442-448
    PubMedGoogle Scholar
  • 28 Vassart G, Dumont J E. The thyrotropin receptor and the regulation of thyrocyte function and growth.  Endocrin Rev. 1992;  13 569-611
    PubMedGoogle Scholar

N. Gómez-Arnaiz, M.D. 

c/ Comte Borrell 20 - 22 3°1a · 08015 Barcelona · Spain

Phone: +34 (93)4430800 ·

Email: 26676nga@comb.es

      >